Navigation Links
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
Date:11/3/2008

ead oncology compound, AEZS-108 in both endometrial and ovarian cancer. The data also strengthens our belief that increased clinical benefit for patients could be achieved by specifically targeting LHRH-receptor expressing tumors using doxorubicin. Finally, this program remains on track and we expect to disclose full results over the next few months."

About the Phase 2 Program

Entitled, "The antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin in women with LHRH-receptor positive gynaecological tumors", this European open-label, non-comparative multi-center Phase 2 program has as its primary endpoint, the partial or complete tumor response rate according to RECIST and/or GCIG guidelines. Secondary endpoints include time to progression, survival, toxicity as well as adverse effects. The program will include up to 82 patients (up to 41 with a diagnosis of platinum-resistant ovarian cancer and up to 41 with disseminated endometrial cancer). Patients are administered an intravenous infusion of 267 mg/m2 of AEZS-108 over a period of 2 hours at a constant rate, every Day 1 of a 21-day (3-week) cycle. The proposed duration of the study treatment is six, three-week cycles. Further information on the program is available at http://www.clinicaltrials.gov.

Prior Phase 1 trial results

On June 3, 2007 positive results of an open, multi-center, sequential group, dose-escalation Phase 1 study in various gynaecological cancers were presented at the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, Illinois. 17 patients with LHRH-receptor positive gynaecological cancers were recruited. AEZS-108 was administered by intravenous infusion over two hours at dosages of 10, 20, 40, 80,160 and 267 mg/m2. At 160 mg/m2, six patients had a total of 32 cycles and at 267 mg/m2, seven patients had a total of 27 cycles. Most of the patients had been pretr
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Grace Century, a private equity ... announces the addition of Dr. Yousef “Josh” Siddiqui ... team. Dr. Siddiqui will provide further healthcare expertise to ... of University College Medical School in the ... in 2001. With further certification as a General Practitioner ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Solutions, LLC, Santa Clara, CA, a manufacturer of ... applications, announced the release of TruTorr(TM), a single-use ... containers, in order to prevent overpressure damage, at ... TruTorr system consists of a disposable pressure sensor, ...
... option for millions of Americans with debilitating lung ... (NYSE: AZN ) today announced that ... approved SYMBICORT (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for ... in patients with chronic obstructive pulmonary disease (COPD), ...
... Is Just What Diabetics Have Been Waiting For. The Sleek, Bold ... By Storm. , ... Greenville, SC (PRWEB) February 27, 2009 -- For ... that is both functional and attractive. In recent years, many companies ...
Cached Biology Technology:Finesse Announces TruTorr(TM) Single-Use Pressure Sensor 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 3FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 4FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 5FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 6Home Delivery Medical Offers New Glucose Meter With State-Of-The-Art Technology 2Home Delivery Medical Offers New Glucose Meter With State-Of-The-Art Technology 3
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... can be cultivated efficiently, they are anything but ... by monoculture cultivation is becoming increasingly evident. Despite ... form and are regarded as the sole possibility ... quite wrongfully, finds Bernhard Schmid, an ecology professor ... novel form of agriculture and forestry. After all, ...
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2
... reports that calcium and vitamin D supplementation improves bone ... who were treated chronically with antiepileptic drugs (AEDs). The ... the International League Against Epilepsy (ILAE), suggest that risedronate, ... when taken with calcium and vitamin D supplementation. ...
... Nanoparticles filled with chemotherapeutic drugs can kill drug-resistant breast ... scientific journal Biomaterials . Nanoparticles are just ... They can therefore pass through the walls of healthy ... drugs against cancer and other diseases. In ...
... leader, Associate Professor Catherine Pickering, said the Griffith study ... which can be dispersed through horse manure. The findings ... and Restoration . "We reviewed 15 studies on ... from North America, three from Australia and one study ...
Cached Biology News:Calcium and vitamin D improve bone density in patients taking antiepileptic drugs 2Nanoparticles can overcome drug resistance in breast cancer cells 2Saddling up against the threat to our National Parks 2
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
... plastic feeding tubes for rodent oral gavage ... risk of perforation and trauma. Plus they ... cleaning and the risk of cross-contamination. ... 20ga Length: ...
Biology Products: